Back

The utility of the MAGGIC heart failure risk score in predicting response to spironolactone: validation and results from the TOPCAT trial

27 May 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Daniel Silverman

Medical University of South Carolina, Charleston (United States of America)

27 More presentations in this session

Presentation thumbnail
Doctor W. Teh (Birmingham, GB)
Abstract Slides
Presentation thumbnail
Presentation thumbnail
Miss R. Mo (Beijing, CN)
Abstract
Presentation thumbnail
Doctor A. Cannata (London, GB)
Abstract Slides
Presentation thumbnail
Doctor E. Santiago Vacas (El Masnou, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome

The Event

Event poster

Heart Failure 2019

27 May 2019 08:30 CET
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
10 July 2023
thumbnail
Congress Presentation
The MAGGIC score in predicting progression of preclinical heart failure in coronary artery disease
20 May 2023
thumbnail
Congress Presentation
A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: the HOMAGE trial
21 May 2023
thumbnail
Congress Presentation
Efficacy of spironolactone in reducing the risk of cardiovascular events and long-term mortality in those with resistant hypertension: findings from the Anglo-Scandinavian Cardiac Outcomes Trial.
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources